SCHEMBL469038

SCHEMBL469038

CS(=O)(=O)c1ccc(C2CCCC2)cc1

nearest known ligand 0.56

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
LMNA P02545 6/20 0.56
HTT P42858 3/20 0.56
PTGS2 P35354 6/20 0.54
SMN1; SMN2 Q16637 4/20 0.53
MAPT P10636 2/20 0.53
ALDH1A1 P00352 2/20 0.53
APOBEC3A P31941 1/20 0.53
APOBEC3G Q9HC16 1/20 0.53
TP53 P04637 1/20 0.53
ATM Q13315 1/20 0.53
XBP1 P17861 1/20 0.48
KMT2A Q03164 2/20 0.47
KDM4E B2RXH2 2/20 0.47
HPGD P15428 1/20 0.47
MAPK1 P28482 1/20 0.45
HSD17B10 Q99714 1/20 0.45
ENPP2 Q13822 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26354332 0.98 LMNA (0.59) LMNAHTTPTGS2SMN1; SMN2MAPT
SCHEMBL10182153 0.98 LMNA (0.59) LMNAHTTPTGS2SMN1; SMN2MAPT
SCHEMBL12473626 0.96 LMNA (0.51) LMNAHTTPTGS2SMN1; SMN2MAPT
SCHEMBL13176976 0.91 PTGS2 (0.51) LMNAHTTPTGS2SMN1; SMN2MAPT
SCHEMBL26154097 0.86 ALOX5AP (0.45) LMNAHTTPTGS2SMN1; SMN2MAPT
SCHEMBL10180298 0.83 LMNA (0.65) LMNAHTTSMN1; SMN2MAPTALDH1A1
SCHEMBL4170969 0.82 SLC18A3 (0.52) PTGS2ENPP2
SCHEMBL22817130 0.82 ESR2 (0.55) LMNAHTTPTGS2SMN1; SMN2MAPT
SCHEMBL22816222 0.82 ESR2 (0.55) LMNAHTTPTGS2SMN1; SMN2MAPT
SCHEMBL6788472 0.82 ESR2 (0.56) LMNAHTTPTGS2SMN1; SMN2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9139456-B2 Chelating compounds and immobilized tethered chelators THE CURATORS OF THE UNIVERSITY OF MISSOURI (US) 2015-09-22 US disclosed
US-20130244122-A1 NONAQUEOUS ELECTROLYTIC SOLUTION AND NONAQUEOUS-ELECTROLYTE BATTERY EMPLOYING THE SAME ONUKI MASAMICHI (JP) 2013-09-19 US disclosed
US-20120219866-A1 NONAQUEOUS ELECTROLYTIC SOLUTION AND NONAQUEOUS-ELECTROLYTE BATTERY EMPLOYING THE SAME MITSUBISHI CHEMICAL CORPORATION (JP) 2012-08-30 US disclosed
EP-2475041-A1 NON-AQUEOUS ELECTROLYTIC SOLUTION, AND NON-AQUEOUS ELECTROLYTE BATTERY COMPRISING SAME Mitsubishi Chemical Corporation (JP) 2012-07-11 EP disclosed
US-20120061325-A1 CHELATING COMPOUNDS AND IMMOBILIZED TETHERED CHELATORS THE CURATORS OF THE UNIVERSITY OF MISSOURI 2012-03-15 US disclosed
US-8066883-B2 Removing aluminum from solution using chelating compounds and immobilized tethered chelators UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) 2011-11-29 US disclosed
US-20110168636-A1 CHELATING COMPOUNDS AND IMMOBILIZED TETHERED CHELATORS THE CURATORS OF THE UNIVERSITY OF MISSOURI 2011-07-14 US disclosed
US-7932326-B2 Chelating compounds and immobilized tethered chelators THE UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) 2011-04-26 US disclosed
US-20090261043-A1 CHELATING COMPOUNDS AND IMMOBILIZED TETHERED CHELATORS THE CURATORS OF THE UNIVERSITY OF MISSOURI 2009-10-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120061325-A1 CHELATING COMPOUNDS AND IMMOBILIZED TETHERED CHELATORS BTD, TTPA, SLC39A7 LMNA 3554/4885HTT 1987/4885PTGS2 4255/4885
US-20090261043-A1 CHELATING COMPOUNDS AND IMMOBILIZED TETHERED CHELATORS BTD, SLC30A7, SLC39A7 LMNA 3626/4885HTT 2384/4885PTGS2 4261/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.